Compare TBB & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBB | HUMAW |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 140990 | 220 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2017 | N/A |
| Metric | TBB | HUMAW |
|---|---|---|
| Price | $22.78 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 14.2K |
| Earning Date | N/A | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.18 |
| 52 Week High | N/A | $1.34 |
| Indicator | TBB | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 48.90 |
| Support Level | $22.50 | $0.10 |
| Resistance Level | $22.68 | $0.15 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 93.85 | 60.18 |
The wireless business contributes nearly 70% of AT&T's revenue. The company is the third-largest US wireless carrier, connecting 74 million postpaid and 17 million prepaid phone customers. Fixed-line enterprise services, which account for about 14% of revenue, include internet access, private networking, security, voice, and wholesale network capacity. Residential fixed-line services, about 12% of revenue, primarily consist of broadband internet access, serving 15 million customers. AT&T also has a sizable presence in Mexico, with 24 million customers, but this business only accounts for 3% of revenue. The company recently sold its 70% equity stake in satellite television provider DirecTV to its partner, private equity firm TPG.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.